RxDoctor Payments Data

Gopi Maharaja, MD

General Practice · Davenport, FLNPI 1649568288

Payments from drug & device makers

$1,783in general payments, 2019–2025

Across 95 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$313
  • Amgen$225
  • Novo Nordisk$222
  • Abbott$199
  • Boehringer Ingelheim$165
  • AstraZeneca$92
  • plus $567 from 17 others

What the payments were for

  • Food & beverage$1,783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,783 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$22,093
Medicare patients
132
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin335$353,813
OzempicSemaglutide160$243,045
OfevNintedanib Esylate11$146,506
EliquisApixaban144$123,065
MounjaroTirzepatide40$52,872
RybelsusSemaglutide29$51,006
FarxigaDapagliflozin Propanediol54$46,628
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$30,311
TrulicityDulaglutide26$29,596
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$28,075
EntrestoSacubitril/Valsartan33$27,543
XareltoRivaroxaban26$23,751
Glipizide ErGlipizide500$11,327
Rosuvastatin Calcium666$10,293
Atorvastatin Calcium1,142$10,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Ofev$165$500,319346 claims
Novo NordiskOzempic, Rybelsus$222$294,051189 claims
PfizerEliquis$35$123,065144 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler$92$86,594133 claims
Lilly USA, LLCMounjaro, Trulicity$313$82,46866 claims
GSKTrelegy Ellipta, Breo Ellipta$46$33,12447 claims
Johnson & JohnsonXarelto$28$23,75126 claims
AbbVieRestasis$70$6,06511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Davenport

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →